摘要:
This document relates to methods and materials for detecting mutations that can be linked to dementia. For example, methods and materials for detecting one or more mutations within PGRN nucleic acid are provided. This document also provides methods and materials for detecting the level of progranulin expression. In addition, this document relates to methods and materials for treating mammals having a neurodegenerative disorder (e.g., dementia). For example, methods and materials for increasing PGRN polypeptide levels in mammals are provided, as are methods and materials for identifying agents that can be used to increase PGRN polypeptide levels in mammals.
摘要:
This document relates to methods and materials for detecting mutations that can be linked to dementia. For example, methods and materials for detecting one or more mutations within PGRN nucleic acid are provided. This document also provides methods and materials for detecting the level of progranulin expression. In addition, this document relates to methods and materials for treating mammals having a neurodegenerative disorder (e.g., dementia). For example, methods and materials for increasing PGRN polypeptide levels in mammals are provided, as are methods and materials for identifying agents that can be used to increase PGRN polypeptide levels in mammals.
摘要:
The invention relates to a polypeptide containing a sequence of contiguous amino acids of the polypeptide sequence coded by exon 17 of the cDNA of the APP 770 gene, with said sequence of contiguous amino acids being such that:it has from 5 to the total number of amino acids coded by said exon 17,and it contains the amino acid corresponding to codon 692 in the cDNA of the APP 770 gene and which is alanine substituted for glycine. (no figure).
摘要:
We previously identified 18q21.33-q23 as a candidate region for bipolar (BP) disorder and constructed a yeast artificial chromosome (YAC) contig map. In a next step we isolated and analysed all CAG/CTG repeats from this region and excluded them from involvement in BP disorder. Here, in the process of identifying all CCG/CGG repeats from the region, we isolated three potential CpG islands, one of which is located 1.5 kb upstream of a predicted exon of 3639 bp. Further analysis showed this was part of a novel CpG-associated, brain-expressed gene, that we called NCAGI (Novel CpG Associated Gene 1). Mutation analysis of this positional and functional candidate identified two single nucleotide polymorphisms, none of which were shown to be associated with the BP phenotype.
摘要:
The invention relates to a process for the in-vitro diagnosis of chromosomal anomalies liable to be correlated with CMT1a disease. The invention also relates to probes intended in this in-vitro diagnosis process and to kits containing said probes. The probes of the invention can contain a sequence constituted of from about 15 successive nucleotides of a Not1 fragment, with said Not1 fragment having 1.2.times.10.sup.6 base pairs and being obtained after digesting human DNA of patients with Not1, separating the fragments resulting from digestion by pulsed field gel electrophoresis and hybridizing the resulting fragments with any of the probes VAW409, EW401 or VAW412 or their derivatives, to about the total number of the successive nucleotides of the Not1 fragment. The probes enable the detection of the duplication of a part of chromosome 17p.
摘要:
We previously identified 18q21.33-q23 as a candidate region for bipolar (BP) disorder and constructed a yeast artificial chromosome (YAC) contig map. In a next step we isolated and analysed all CAG/CTG repeats from this region and excluded them from involvement in BP disorder. Here, in the process of identifying all CCG/CGG repeats from the region, we found a cluster of 6 genes encoding for serpins. For one of them, CAP2 located at 18q21.3, a mutation analysis was performed. Analysis of the thus identified single nucleotide polymorphisms (six in total) revealed a statistically significant association of SNP c.942G>T with BP disorder. It is thus an object of the present invention to provide a method of diagnosing BP or susceptibility to BP in an individual which method comprises determining, in a sample from the individual, the single nucleotide polymorphism in the CAP2 gene of the individual, and determining the status of the individual by reference to polymorphism in the CAP2 gene.